Plain-English translation of NCT07886047 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing —a medication commonly used to treat high blood pressure and heart conditions—in combination with immunotherapy and for patients with small cell lung cancer. The researchers believe this medication may help boost your immune system's ability to fight cancer when used alongside these other treatments. The study will examine whether this combination is safe and whether it helps patients with both early-stage and advanced lung cancer.
Small cell lung cancer is an aggressive cancer that needs new treatment approaches. Early research suggests that this medication may strengthen the immune system's response to immunotherapy, potentially making these cancer treatments more effective than they currently are.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as a daily oral pill at increasing dose levels, combined with immunotherapy and infusions every three weeks. Treatment typically lasts 4–6 cycles (3–4 months), followed by ongoing maintenance therapy with the medication and immunotherapy alone for up to two years or until your cancer improves or side effects become unmanageable. You will have regular blood tests, heart monitoring, and imaging scans to track your health and how well the treatment is working.
AI-generated summary from trial data · Nov 17, 2026 · Not medical advice
China